429 related articles for article (PubMed ID: 16776751)
1. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Ratner RE; Maggs D; Nielsen LL; Stonehouse AH; Poon T; Zhang B; Bicsak TA; Brodows RG; Kim DD
Diabetes Obes Metab; 2006 Jul; 8(4):419-28. PubMed ID: 16776749
[TBL] [Abstract][Full Text] [Related]
3. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin.
Riddle MC; Henry RR; Poon TH; Zhang B; Mac SM; Holcombe JH; Kim DD; Maggs DG
Diabetes Metab Res Rev; 2006; 22(6):483-91. PubMed ID: 16634116
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
[TBL] [Abstract][Full Text] [Related]
5. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
Klonoff DC; Buse JB; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Wintle ME; Maggs DG
Curr Med Res Opin; 2008 Jan; 24(1):275-86. PubMed ID: 18053320
[TBL] [Abstract][Full Text] [Related]
6. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
[TBL] [Abstract][Full Text] [Related]
8. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
Kendall DM; Riddle MC; Rosenstock J; Zhuang D; Kim DD; Fineman MS; Baron AD
Diabetes Care; 2005 May; 28(5):1083-91. PubMed ID: 15855571
[TBL] [Abstract][Full Text] [Related]
9. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
10. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
Buse JB; Henry RR; Han J; Kim DD; Fineman MS; Baron AD;
Diabetes Care; 2004 Nov; 27(11):2628-35. PubMed ID: 15504997
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Yuan GH; Song WL; Huang YY; Guo XH; Gao Y
Chin Med J (Engl); 2012 Aug; 125(15):2677-81. PubMed ID: 22931974
[TBL] [Abstract][Full Text] [Related]
12. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Nelson P; Poon T; Guan X; Schnabel C; Wintle M; Fineman M
Diabetes Technol Ther; 2007 Aug; 9(4):317-26. PubMed ID: 17705687
[TBL] [Abstract][Full Text] [Related]
13. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
Nauck MA; Duran S; Kim D; Johns D; Northrup J; Festa A; Brodows R; Trautmann M
Diabetologia; 2007 Feb; 50(2):259-67. PubMed ID: 17160407
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
[TBL] [Abstract][Full Text] [Related]
15. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
16. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
18. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
Mikhail N
Expert Opin Investig Drugs; 2008 Jun; 17(6):845-53. PubMed ID: 18491986
[TBL] [Abstract][Full Text] [Related]
19. Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Wysham CH; MacConell LA; Maggs DG; Zhou M; Griffin PS; Trautmann ME
Mayo Clin Proc; 2015 Mar; 90(3):356-65. PubMed ID: 25744115
[TBL] [Abstract][Full Text] [Related]
20. Exenatide: new drug. Type 2 diabetes for some overweight patients.
Prescrire Int; 2007 Dec; 16(92):228-31. PubMed ID: 18087791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
